-
Media Release
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
-
Media Release
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
-
Media Release
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
-
Media Release
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
-
Media Release
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
-
Media Release
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
-
Media Release
Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
-
Media Release
Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
-
Media Release
Novartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia
-
Media Release
Novartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia
-
Media Release
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
-
Media Release
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®